Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Lebanon has been on the rise in recent years.
Customer preferences: Patients suffering from autoimmune diseases, organ transplants, and cancer are the primary customers of immunosuppressants. In Lebanon, the market for immunosuppressants is driven by a growing number of patients with autoimmune diseases and a rising number of organ transplant surgeries. Patients with autoimmune disorders require long-term treatment with immunosuppressants to prevent the immune system from attacking the body's healthy cells. Organ transplant recipients also require immunosuppressants to prevent their immune system from rejecting the transplanted organ.
Trends in the market: The immunosuppressants market in Lebanon has been growing steadily due to an increase in the number of patients with autoimmune diseases and organ transplant surgeries. The market is dominated by branded drugs, but there is an increasing trend towards generic drugs due to their lower cost. The government is also taking steps to reduce the cost of immunosuppressants by introducing price controls and encouraging the use of generic drugs.
Local special circumstances: Lebanon has been facing economic and political instability in recent years, which has had a significant impact on the healthcare sector. The country has been facing a shortage of foreign currency, which has led to a shortage of medical supplies, including immunosuppressants. The COVID-19 pandemic has also had a significant impact on the healthcare sector, with hospitals overwhelmed with COVID-19 patients and a shortage of medical supplies.
Underlying macroeconomic factors: The healthcare sector in Lebanon has been facing significant challenges due to the economic and political instability in the country. The Lebanese pound has lost more than 80% of its value in the past two years, leading to a shortage of foreign currency and a rise in inflation. The healthcare sector has been hit hard by the economic crisis, with hospitals struggling to pay for medical supplies and equipment. The government is taking steps to address the crisis by introducing price controls and providing subsidies for essential medicines. However, the long-term sustainability of the healthcare sector remains a significant challenge.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
